J Korean Med Assoc.  2014 Sep;57(9):780-788. 10.5124/jkma.2014.57.9.780.

Pneumococcal vaccine

• Song JY
• Cheong HJ

• KMID: 2459287
• DOI: http://doi.org/10.5124/jkma.2014.57.9.780

Abstract

Streptococcus pneumoniae (pneumococcus) is an important pathogen with high morbidity and mortality worldwide. Pneumococcal vaccine is an important measure to reduce the pneumococcal disease burden. Currently, two pneumococcal vaccines are available in adults, including 23-valent pneumococcal polysaccharide vaccine (PPV23) and 13-valent pneumococcal protein-conjugate vaccine (PCV13). PCV13 consists of capsular polysaccharides derived from the 13 most common types that cause invasive diseases (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F). PPV23 covers 10 additional serotypes compared to PCV13, but it does not include serotype 6A. Even though limited in the number of serotypes, PCV13 has several important advantages over PPV23: T-cell dependent superior immunogenicity, booster effect, absence of hypo-responsiveness and protective effect on pneumonia. Although PPV23 is effective to prevent 50% to 80% of invasive pneumococcal diseases, it may be ineffective for high-risk immunocompetent and immunocompromised patients. In adults, the choice of pneumococcal vaccine should be based on the severity of underlying medical conditions and local serotype distribution. Serotype distribution is quite variable temporally and geographically. Continuous sero-surveillance is essential for the establishment of optimal vaccination strategy.

Keyword

Pneumococcal vaccines; Streptococcus pneumoniae; Pneumococcal infections

MeSH Terms

Adult
Humans
Immunocompromised Host
Mortality
Pneumococcal Infections
Pneumococcal Vaccines
Pneumonia
Polysaccharides
Streptococcus pneumoniae
T-Lymphocytes
Vaccination
Pneumococcal Vaccines
Polysaccharides

Reference

1. Song JH, Jung KS. Treatment guidelines for community-acquired pneumonia in Korea: an evidence-based approach to appropriate antimicrobial therapy. J Korean Med Assoc. 2010; 53:20–42.

2. Song JY, Choi JY, Lee JS, Bae IG, Kim YK, Sohn JW, Jo YM, Choi WS, Lee J, Park KH, Kim WJ, Cheong HJ. Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study. BMC Infect Dis. 2013; 13:202.

3. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 2012; 307:804–812.

4. Van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, Miller E. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012; 65:17–24.

5. Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005; 192:377–386.

6. Pelton SI, Weycker D, Farkouh RA, Shea KM, Edelsberg J, Strutton DR. Relative rates of pneumococcal disease are disproportionately high in adults with multiple chronic medical conditions. In : Kenes International. Proceedings of 9th International Symposium on Pneumococci and Pneumococcal Diseases; 2014 Mar 9-13; Hyderabad, India. Geneva: Kenes International;2014. p. OP-390.

7. Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci. 2013; 28:4–15.

8. Poolman JT, Peeters CC, van den Dobbelsteen GP. The history of pneumococcal conjugate vaccine development: dose selection. Expert Rev Vaccines. 2013; 12:1379–1394.

9. Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, Pollard AJ. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012; 205:1408–1416.

10. Poolman J, Frasch C, Nurkka A, Kayhty H, Biemans R, Schuerman L. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines. Clin Vaccine Immunol. 2011; 18:327–336.

11. Cho EY, Kang HM, Lee J, Kang JH, Choi EH, Lee HJ. Changes in serotype distribution and antibiotic resistance of nasopharyngeal isolates of Streptococcus pneumoniae from children in Korea, after optional use of the 7-valent conjugate vaccine. J Korean Med Sci. 2012; 27:716–722.

12. Song JY, Moseley MA, Burton RL, Nahm MH. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. 2013; 19:412–425.

13. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009; 180:48–58.

14. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008; (1):CD000422.

15. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012; 30:6802–6808.

16. Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults. Drugs. 2012; 72:1243–1255.

17. Lee H, Choi EH, Lee HJ. Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines. Korean J Pediatr. 2014; 57:55–66.

18. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, Mwaiponya M, Zijlstra EE, Molyneux ME, Gilks CF. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010; 362:812–822.

19. Fedson DS. Preventing non bacteremic pneumococcal pneumonia in older adults: Historical background and considerations for choosing between PCV13 and PPV23. Hum Vaccin Immunother. 2014; 04. 14. [Epub]. http://dx.doi.org/10.4161/hv.28797.

20. Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines. 2011; 10:1143–1167.

21. Kim SH, Song JH, Chung DR, Thamlikitkul V, Yang Y, Wang H, Lu M, So TM, Hsueh PR, Yasin RM, Carlos CC, Pham HV, Lalitha MK, Shimono N, Perera J, Shibl AM, Baek JY, Kang CI, Ko KS, Peck KR. ANSORP Study Group. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012; 56:1418–1426.

22. Grabenstein JD, Weber DJ. Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake. Clin Infect Dis. 2014; 58:854–864.

23. Lee S, Bae S, Lee KJ, Yu JY, Kang Y. Changes in serotype prevalence and antimicrobial resistance among invasive Streptococcus pneumoniae isolates in Korea, 1996-2008. J Med Microbiol. 2013; 62(Pt 8):1204–1210.

24. Song JY, Nahm MH, Cheong HJ, Kim WJ. Impact of preceding flu-like illness on the serotype distribution of pneumococcal pneumonia. PLoS One. 2014; 9:e93477.

25. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012; 61:816–819.

26. Recommended immunization schedule for adults in Korea, by the Korean Society of Infectious Diseases, 2012. Clin Exp Vaccine Res. 2014; 3:110–112.

27. Bridges CB, Coyne-Beasley T. Advisory Committee on Immunization Practices. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2014. Ann Intern Med. 2014; 160:190.

28. Ordonez JE, Orozco JJ. Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia. BMC Infect Dis. 2014; 14:172.

29. Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine. 2012; 30:5437–5444.

30. Wu DB, Roberts CS, Huang YC, Chien L, Fang CH, Chang CJ. A retrospective study to assess the epidemiological and economic burden of pneumococcal diseases in adults aged 50 years and older in Taiwan. J Med Econ. 2014; 17:312–319.

31. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG. Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005; 294:2043–2051.